Mauritio
Member
- Joined
- Feb 26, 2018
- Messages
- 5,669
The good selegiline studies just keep on increasing in the last months. This one is really interesting. It showed that selegiline prevented weight gain on a high fat diet. On a normal diet it also lead to weight loss. The animals consumed more food ,and weighed less. Selegiline increased UCP1 and AMPK amongst others.
"The effect was evaluated through an assessment of body energy homeostasis, glucose tolerance tests, and biochemical analysis. Pharmacological inhibition of MAO-B by selegiline was observed to reduce body weight and fat accumulation, and improved glucose metabolism without a corresponding change in food intake, in HFD-fed obese mice. We also observed that both the expression of adipogenenic markers, including C/EBPα and FABP4, and lipogenic markers such as pACC were significantly reduced in epididymal white adipose tissues (eWATs). Conversely, increased expression of lipolytic markers such as ATGL and pHSL and AMPK phosphorylation were noted. Treating obese mice with selegiline significantly increased expression levels of UCP1 and promoted eWAT browning, indicating increased energy expenditure. These results suggest that selegiline, by inhibiting MAO-B activity, is a potential anti-obesity treatment."
In another study haidut posted selegiline was relatively ineffective for weight loss, the authors say that might be, because the central inhibition of MAO-B is much more effective than the peripheral inhibition, and apparently selegiline does not cross the BBB very effectively. In the case of this study they used very high doses (200mg HED) which might simply overpower the BBB and lead to a higher brain concentration. It might also be that it caused changes in the microbiome which another study has shown. It increased Akkermansia a lot which has been shown to lead to weight loss.
- Selegiline Modulates Lipid Metabolism by Activating AMPK Pathways of Epididymal White Adipose Tissues in HFD-Fed Obese Mice
"The effect was evaluated through an assessment of body energy homeostasis, glucose tolerance tests, and biochemical analysis. Pharmacological inhibition of MAO-B by selegiline was observed to reduce body weight and fat accumulation, and improved glucose metabolism without a corresponding change in food intake, in HFD-fed obese mice. We also observed that both the expression of adipogenenic markers, including C/EBPα and FABP4, and lipogenic markers such as pACC were significantly reduced in epididymal white adipose tissues (eWATs). Conversely, increased expression of lipolytic markers such as ATGL and pHSL and AMPK phosphorylation were noted. Treating obese mice with selegiline significantly increased expression levels of UCP1 and promoted eWAT browning, indicating increased energy expenditure. These results suggest that selegiline, by inhibiting MAO-B activity, is a potential anti-obesity treatment."
In another study haidut posted selegiline was relatively ineffective for weight loss, the authors say that might be, because the central inhibition of MAO-B is much more effective than the peripheral inhibition, and apparently selegiline does not cross the BBB very effectively. In the case of this study they used very high doses (200mg HED) which might simply overpower the BBB and lead to a higher brain concentration. It might also be that it caused changes in the microbiome which another study has shown. It increased Akkermansia a lot which has been shown to lead to weight loss.
- Selegiline Modulates Lipid Metabolism by Activating AMPK Pathways of Epididymal White Adipose Tissues in HFD-Fed Obese Mice